GLP-1アナログ市場：薬剤タイプ別、ブランド別、用途別、投与経路別、タイプ別、性別、年齢層別、流通チャネル別、地域別

GLP-1アナログ市場は、2025年に535億米ドルと推定され、2032年には1,044億4,000万米ドルに達すると予測され、2025～2032年までのCAGRは10.1%で成長する見込みです。

GLP-1アナログ市場は、2型糖尿病と肥満管理の治療パラダイムを根本的に変革する、糖尿病治療薬の展望における革命的なセグメントです。GLP-1アナログは、天然に存在するインクレチンホルモンであるGLP-1の合成品であり、インスリン分泌を刺激し、グルカゴン分泌を抑制し、胃排出を遅らせることにより、グルコースの恒常性維持に重要な役割を果たしています。これらの革新的な治療薬は、血糖コントロールと大幅な体重減少という2つの作用機序を併せ持つことから、基礎治療薬として台頭してきました。

この市場には、1日1回投与製剤、週1回投与製剤、長時間作用型製剤などさまざまな製剤があり、患者の嗜好や治療プロトコルの多様性に対応しています。主要企業は、薬効を高め、副作用を軽減し、高度なデリバリーシステムを通じて患者のコンプライアンスを向上させるため、研究開発に多額の投資を行っています。世界の糖尿病有病率の増加と肥満関連合併症に対する意識の高まりにより、GLP-1アナログはヘルスケアプロバイダーの間で好ましい治療選択肢として位置付けられています。この市場セグメントは、心血管リスクの低減や神経保護作用の可能性など、臨床応用の拡大により力強い成長を続けており、現代の医薬品業界で最もダイナミックで急速に発展している分野の1つとなっています。

市場力学

GLP-1アナログ市場は、その力強い成長軌道を裏付けるいくつかの強力な促進要因によって支えられています。その第一の要因は、2型糖尿病と肥満の世界の有病率の上昇であり、現在、世界中で5億3,700万人以上の成人が糖尿病を患っており、効果的な治療介入に対するかつてない需要が生じています。GLP-1アナログの優れた有効性プロファイルは、大幅な体重減少効果とともにHbA1cの有意な低下を示し、これらの薬剤は従来の糖尿病治療薬よりも好ましい治療選択肢として位置付けられています。さらに、心血管保護作用や非アルコール性脂肪性肝疾患（NAFLD）への応用の可能性を支持する臨床エビデンスの拡大により、治療領域の幅が広がり、市場導入の原動力となっています。徐放性製剤や革新的な注射デバイスを含むドラッグデリバリーシステムの技術的進歩は、患者の利便性とアドヒアランスを高め、市場成長をさらに刺激します。しかし、GLP-1アナログ製剤は従来の糖尿病治療薬に比べて高価であるため、特に価格に敏感な市場においては入手の障壁となり、特定の地域では保険適用が制限されるなど、市場は顕著な抑制要因に直面しています。

吐き気、嘔吐、下痢などの消化器系の副作用は、患者のコンプライアンスや治療継続に影響を与え、市場浸透の妨げになる可能性があります。ペプチドベース生物製剤の製造の複雑さは、サプライチェーン上の課題とコストへの影響をもたらします。しかしながら、医療インフラの改善や保険適用範囲の拡大と相まって糖尿病有病率が急速に上昇している新興経済諸国の未開拓市場からは、大きなビジネスチャンスが生まれています。GLP-1アナログと他の糖尿病治療薬との併用療法の可能性は、有利な発展機会をもたらします。さらに、アルツハイマー病、パーキンソン病、その他の代謝性疾患を含む新規適応症の研究が進行中であり、GLP-1アナログを糖尿病管理以外の汎用性の高い治療プラットフォームとして位置づけることで、対応可能な市場が大幅に拡大する可能性があります。

本調査の主な特徴

• 本レポートでは、世界のGLP-1アナログ市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模および複合年間成長率（CAGR%）を示します。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて、世界のGLP-1アナログ市場の主要企業プロファイルを掲載しています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• この調査レポートは、投資家、サプライヤー、製品メーカー、販売業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者を対象としています。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 促進要因
• 抑制要因
• 機会
• 影響分析
• 主な発展
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ
• 業界動向

第4章 世界のGLP-1アナログ市場：薬剤タイプ別、2020～2032年

• セマグルチド
• リラグルチド
• エキセナチド
• デュラグルチド
• チルゼパチド
• リナグリプチン
• リキシセナチド
• その他

第5章 世界のGLP-1アナログ市場：ブランド別、2020～2032年

• サクセンダ
• ヴィクトザ
• オゼンピック
• ウゴービ
• リベルサス
• トルリシティペン
• ゼップバウンド
• マンジャロ
• ビデュリオンBCise
• その他

第6章 世界のGLP-1アナログ市場：用途別、2020～2032年

• 2型糖尿病
• 体重管理（肥満/過体重）
• 心血管リスクの軽減

第7章 世界のGLP-1アナログ市場：投与経路別、2020～2032年

• 経口
• 非経口

第8章 世界のGLP-1アナログ市場：タイプ別、2020～2032年

• 先発品
• ジェネリック

第9章 世界のGLP-1アナログ市場：性別、2020～2032年

• 男性
• 女性

第10章 世界のGLP-1アナログ市場：年齢層別、2020～2032年

• 成人
• 小児

第11章 世界のGLP-1アナログ市場：流通チャネル別、2020～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第12章 世界のGLP-1アナログ市場：地域別、2020～2032年

• 北米
  • 米国
  • カナダ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • メキシコ
  • その他ラテンアメリカ
• 欧州
  • ドイツ
  • 英国
  • スペイン
  • フランス
  • イタリア
  • ロシア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • ASEAN
  • その他アジア太平洋地域
• 中東
  • GCC諸国
  • イスラエル
  • その他中東
• アフリカ
  • 南アフリカ
  • 北アフリカ
  • 中央アフリカ

第13章 競合情勢

• Novo Nordisk
• Eli Lilly and Company
• Sanofi
• AstraZeneca
• Boehringer Ingelheim
• Merck & Co.
• Amgen
• GlaxoSmithKline
• Bristol-Myers Squibb
• Takeda Pharmaceutical Company
• Daiichi Sankyo
• Pfizer
• Teva Pharmaceutical Industries
• Regeneron Pharmaceuticals
• Intarcia Therapeutics
• Hngzhou Jiuyuan Gene Engineering Co Ltd

第14章 アナリストの推奨事項

• 機会
• アナリストの見解
• Coherent Opportunity Map

第15章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Glucagon Like Peptide 1 Analogs Market is estimated to be valued at USD 53.50 Bn in 2025 and is expected to reach USD 104.44 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.1% from 2025 to 2032.

The glucagon like peptide 1 analogs market represents a revolutionary segment within the diabetes therapeutics landscape, fundamentally transforming treatment paradigms for Type 2 diabetes mellitus and obesity management. GLP-1 analogs are synthetic versions of the naturally occurring incretin hormone GLP-1, which plays a crucial role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. These innovative therapeutic agents have emerged as cornerstone treatments due to their dual mechanism of action, offering both glycemic control and significant weight reduction benefits.

The market encompasses various formulations including once-daily, once-weekly, and emerging longer-acting preparations, catering to diverse patient preferences and treatment protocols. Leading pharmaceutical companies have invested heavily in research and development to enhance drug efficacy, reduce side effects, and improve patient compliance through advanced delivery systems. The growing prevalence of diabetes worldwide, coupled with increasing awareness of obesity-related comorbidities, has positioned GLP-1 analogs as preferred therapeutic options among healthcare providers. This market segment continues to witness robust growth driven by expanding clinical applications, including cardiovascular risk reduction and potential neuroprotective effects, making it one of the most dynamic and rapidly evolving sectors in modern pharmaceutical industry.

Market Dynamics

The glucagon like peptide 1 analogs market is propelled by several compelling drivers that underscore its robust growth trajectory. The primary driver is the escalating global prevalence of Type 2 diabetes and obesity, with over 537 million adults currently living with diabetes worldwide, creating an unprecedented demand for effective therapeutic interventions. The superior efficacy profile of GLP-1 analogs, demonstrating significant HbA1c reduction alongside substantial weight loss benefits, positions these agents as preferred treatment options over traditional diabetes medications. Additionally, expanding clinical evidence supporting cardiovascular protective effects and potential applications in non-alcoholic fatty liver disease (NAFLD) broadens the therapeutic scope, driving market adoption. Technological advancements in drug delivery systems, including extended-release formulations and innovative injection devices, enhance patient convenience and adherence, further stimulating market growth. However, the market faces notable restraints, primarily the high cost of GLP-1 analogs compared to conventional diabetes treatments, creating accessibility barriers particularly in price-sensitive markets and limiting insurance coverage in certain regions.

Gastrointestinal side effects, including nausea, vomiting, and diarrhea, can impact patient compliance and treatment continuation, potentially hindering market penetration. Manufacturing complexities associated with peptide-based biologics pose supply chain challenges and cost implications. Nevertheless, significant opportunities emerge from untapped markets in developing economies where diabetes prevalence is rapidly increasing, coupled with improving healthcare infrastructure and expanding insurance coverage. The potential for combination therapies integrating GLP-1 analogs with other diabetes medications presents lucrative development opportunities. Furthermore, ongoing research into novel indications including Alzheimer's disease, Parkinson's disease, and other metabolic disorders could substantially expand the addressable market, positioning GLP-1 analogs as versatile therapeutic platforms beyond diabetes management.

Key Features of the Study

• This report provides an in-depth analysis of the global glucagon like peptide 1 analogs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global glucagon like peptide 1 analogs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck & Co., Amgen, GlaxoSmithKline, Bristol-Myers Squibb, Takeda Pharmaceutical Company, Daiichi Sankyo, Pfizer, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Intarcia Therapeutics, and Hngzhou Jiuyuan Gene Engineering Co Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global glucagon like peptide 1 analogs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Market Segmentation

• Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Semaglutide
  • Liraglutide
  • Exenatide
  • Dulaglutide
  • Tirzepatide
  • Others
  • Linagliptin
  • Lixisenatide
• Brand Insights (Revenue, USD Bn, 2020 - 2032)
  • Saxenda
  • Victoza
  • Ozempic
  • Wegovy
  • Rybelsus
  • Trulicity Pen
  • Zepbound
  • Mounjaro
  • BYDUREON BCise
  • Others
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Type 2 Diabetes Mellitus
  • Weight Management (Obesity/Overweight)
  • Cardiovascular Risk Reduction
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Parenteral
• Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Brand
  • Generic
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Pediatric/Children
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi
  • AstraZeneca
  • Boehringer Ingelheim
  • Merck & Co.
  • Amgen
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical Company
  • Daiichi Sankyo
  • Pfizer
  • Teva Pharmaceutical Industries
  • Regeneron Pharmaceuticals
  • Intarcia Therapeutics
  • Hngzhou Jiuyuan Gene Engineering Co Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Glucagon Like Peptide 1 Analogs Market, By Drug Type
  • Glucagon Like Peptide 1 Analogs Market, By Brand
  • Glucagon Like Peptide 1 Analogs Market, By Application
  • Glucagon Like Peptide 1 Analogs Market, By Route of Administration
  • Glucagon Like Peptide 1 Analogs Market, By Type
  • Glucagon Like Peptide 1 Analogs Market, By Gender
  • Glucagon Like Peptide 1 Analogs Market, By Age Group
  • Glucagon Like Peptide 1 Analogs Market, By Distribution Channel
  • Glucagon Like Peptide 1 Analogs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Semaglutide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Liraglutide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Exenatide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Dulaglutide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Tirzepatide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Linagliptin
• Lixisenatide

5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Saxenda
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Victoza
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Ozempic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Wegovy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rybelsus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Trulicity Pen
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Zepbound
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Mounjaro
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• BYDUREON BCise
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Glucagon Like Peptide 1 Analogs Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Type 2 Diabetes Mellitus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Weight Management (Obesity/Overweight)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cardiovascular Risk Reduction
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Glucagon Like Peptide 1 Analogs Market, By Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Brand
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Generic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pediatric/Children
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

13. Competitive Landscape

• Novo Nordisk
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Daiichi Sankyo
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Intarcia Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hngzhou Jiuyuan Gene Engineering Co Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

14. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

15. References and Research Methodology

• References
• Research Methodology
• About us